82 related articles for article (PubMed ID: 9615813)
1. Lack of correlation between tumor markers (CA 125 and SCC) and systemic lupus erythematosus activity.
Miret C; Font J; Molina R; Filella X; Vivancos J; Muñoz-Rodriguez FJ; Cervera R; Ballesta AM; Ingelmo M
Anticancer Res; 1998; 18(2B):1341-4. PubMed ID: 9615813
[TBL] [Abstract][Full Text] [Related]
2. Ascites is the primary cause of cancer antigen-125 (CA-125) elevation in systemic lupus erythematosus (SLE) patients with nephrotic syndrome.
Basaran A; Zafer Tuncer S
Med Hypotheses; 2007; 68(1):197-201. PubMed ID: 16979301
[TBL] [Abstract][Full Text] [Related]
3. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
6. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
8. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity.
Leaños-Miranda A; Cárdenas-Mondragón G
Rheumatology (Oxford); 2006 Jan; 45(1):97-101. PubMed ID: 16249247
[TBL] [Abstract][Full Text] [Related]
9. Correlation of serum measures of nitric oxide production with lupus disease activity.
Gilkeson G; Cannon C; Oates J; Reilly C; Goldman D; Petri M
J Rheumatol; 1999 Feb; 26(2):318-24. PubMed ID: 9972965
[TBL] [Abstract][Full Text] [Related]
10. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
12. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
14. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
[TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinoma antigen serum levels as prognostic parameter in patients with early stage vulvar cancer.
Hefler LA; Sliutz G; Leodolter S; Speiser P; Joura E; Reinthaller A; Kohlberger P
Gynecol Oncol; 2005 Jun; 97(3):904-7. PubMed ID: 15894354
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
17. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
18. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation.
Nägele H; Bahlo M; Klapdor R; Rödiger W
Anticancer Res; 1999; 19(4A):2531-4. PubMed ID: 10470189
[TBL] [Abstract][Full Text] [Related]
19. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
20. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
